This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
CHARM-Added was a randomized, double-blind, phase 3 parallel trial evaluating candesartan cilexetil compared with placebo for congestive heart failure.
| Feature | CHARM-Added |
|---|---|
| Phase | Phase 3 |
| Condition | Congestive Heart Failure |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | Double |
| Primary purpose | Treatment |
| Lead sponsor | AstraZeneca |
2. Clinical Question
Population
Patients with congestive heart failure enrolled in the randomized phase 3 study.
Intervention
Candesartan cilexetil.
Comparator
Placebo.
Primary question
Does candesartan change the occurrence of cardiovascular mortality or hospitalization due to congestive heart failure compared with placebo?
3. Trial Design
Randomization
597 patients
Double-blind
Two arms
Treatment
Candesartan vs placebo
Follow-up
Up to 24 months
Candesartan arm
Randomized treatment with candesartan cilexetil.
Placebo arm
Randomized comparator treatment with placebo.
4. Endpoints
| Endpoint | Registry definition | Time frame |
|---|---|---|
| Primary endpoint | Cardiovascular mortality or hospitalisation due to congestive heart failure | 2, 4, 6 weeks, 6 months, every 4 months thereafter until 24 months |
5. Planned Analysis
The ClinicalTrials.gov record identifies the primary endpoint as a cardiovascular mortality or congestive heart failure hospitalization outcome assessed repeatedly through 24 months. No posted statistical analyses are available in the registry record.
For a time-to-event composite endpoint of this type, statistical analysis commonly compares event occurrence between randomized groups using survival analysis methods. These approaches account for differences in follow-up time and censoring when estimating treatment effects.
6. Statistical Methodology
Composite clinical endpoints
The primary endpoint combines cardiovascular mortality and hospitalization due to congestive heart failure. A composite endpoint evaluates whether a patient experiences the first occurrence of any component event.
The interpretation of a composite endpoint depends on the clinical importance and frequency of each component. Individual components should be considered separately when results are available.
Randomization
Random allocation helps balance measured and unmeasured characteristics between treatment groups, allowing the comparison to focus on the assigned intervention.
Double-blind design
Blinding reduces the possibility that knowledge of treatment assignment influences patient management, outcome assessment, or reporting of symptoms.
7. Statistical Methods Explained
Why use a randomized design?
Randomization creates comparable groups at baseline and supports unbiased estimation of differences between assigned treatments.
Why analyze hospitalization and mortality together?
A composite endpoint can capture multiple clinically important outcomes, although interpretation requires understanding the contribution of each component.
Why are repeated follow-up assessments important?
Events may occur at different times after randomization. Repeated assessment allows investigators to observe outcomes throughout the planned follow-up period.
What does censoring mean in survival analysis?
Censoring occurs when follow-up ends before an event is observed. Survival methods incorporate available follow-up information without assuming that every patient experiences the event.
8. Limitations
- The ClinicalTrials.gov record does not report posted statistical analyses or endpoint estimates.
- Without posted effect estimates, confidence intervals, or p-values, treatment-effect magnitude cannot be interpreted from the registry record.
- Composite endpoints require interpretation of the individual clinical events contributing to the composite outcome.
- Registry information does not include additional statistical analysis details such as multiplicity procedures, missing-data methods, or interim-analysis plans.
9. Why This Trial Matters Statistically
CHARM-Added illustrates several important principles in clinical-trial statistics: randomized treatment comparisons, blinded assessment, parallel-group design, and analysis of clinically meaningful composite outcomes.
| Concept | Application |
|---|---|
| Randomization | Comparison of candesartan and placebo groups |
| Blinding | Double-blind treatment assignment |
| Composite endpoint | Cardiovascular mortality or hospitalization due to congestive heart failure |
| Longitudinal follow-up | Assessment through 24 months |
10. Sources
- ClinicalTrials.gov record: NCT00634309